Treatment of hypercalcaemia associated with malignancy.
- 17 March 1984
- Vol. 288 (6420) , 812-813
- https://doi.org/10.1136/bmj.288.6420.812
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- COMPARISON OF INTRAVENOUS (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE AND VOLUME REPLETION IN TUMOUR-INDUCED HYPERCALCAEMIAThe Lancet, 1983
- Comparative study of available medical therapy for hypercalcemia of malignancyThe American Journal of Medicine, 1983
- Disequilibrium hypercalcaemia.BMJ, 1983
- Comparison of two parenteral diphosphonates in hypercalcemia of malignancyThe American Journal of Medicine, 1982
- Effect of Calcitonin and Glucocorticoids in Combination on the Hypercalcemia of MalignancyAnnals of Internal Medicine, 1980
- EFFECT OF DICHLOROMETHYLENE DIPHOSPHONATE IN PAGET'S DISEASE OF BONE AND IN HYPERCALCÆMIA DUE TO PRIMARY HYPERPARATHYROIDISM OR MALIGNANT DISEASEThe Lancet, 1980
- Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.Journal of Clinical Investigation, 1980
- INHIBITION OF OSTEOLYTIC BONE LESIONS BY (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)The Lancet, 1979
- Drugs for Disorders of BoneDrugs, 1974
- FAILURE OF CORTICOSTEROID THERAPY TO CORRECT THE HYPERCALCÆMIA OF MALIGNANT DISEASEThe Lancet, 1970